aot2022v55i1

More documents

Recommendations

Info

Acta Oncologica Turcica 2022; 55: 1-88Neoplastic Hematopathology Baltimore, MD,Williams & Wilkins. 1992.27. Conlan MG, Bast M, Armitage JO,Weisenburger DD. Bone marrow involvement bynon-Hodgkin's lymphoma: the clinicalsignificance of morphologic discordance betweenthe lymph node and bone marrow. NebraskaLymphoma Study Group. Journal of ClinicalOncology. 1990; 8: 1163-72.28. Foucar K, McKenna RW, Frizzera G, BrunningRD. Bone marrow and blood involvement bylymphoma in relationship to the Lukes-Collinsclassification. Cancer. 1982; 49: 888-97.29. McKenna RW, Bloomfield CD, Brunning RD.Nodular lymphoma: bone marrow and bloodmanifestations. Cancer. 1975; 36: 428-40.30. Ribrag V, Vanel D, Leboulleux S, Lumbroso J,Couanet D, Bonniaud G, et al. Prospective studyof bone marrow infiltration in aggressivelymphoma by three independent methods:whole-body MRI, PET/CT and bone marrowbiopsy. European Journal of Radiology. 2008; 66:325-31.31. Kwee TC, Kwee RM, Nievelstein RA. Imagingin staging of malignant lymphoma: a systematicreview. Blood. 2008; 111: 504-16.32. Özpolat HT, Yilmaz E, Goksoy HS, Özpolat S,Dogan Ö, Unal SN, et al. Detection of bonemarrow involvement with FDG PET/CT in patientswith newly diagnosed lymphoma. BloodResearch. 2018; 53: 281-7.33. Ellis ME, Diehl LF, Granger E, Elson E. Trephineneedle bone marrow biopsy in the initial stagingof Hodgkin disease: sensitivity and specificity ofthe Ann Arbor staging procedure criteria.American Journal of Hematology. 1989; 30 :115-20.34. Coller BS, Chabner BA, Gralnick HR.Frequencies and patterns of bone marrowinvolvement in non‐Hodgkin lymphomas:Observations on the value of bilateral biopsies.American Journal of Hematology. 1977; 3: 105-19.35. Brunning Rd, Bloomfield Cd, Mckenna Rw,Peterson L. Bilateral trephine bone marrowbiopsies in lymphoma and other neoplasticdiseases. Annals of Internal Medicine. 1975; 82:365-6.36. Muslimani AA, Farag HL, Francis S, Spiro TP,Chaudhry AA, Chan VC, et al. The utility of 18-Ffluorodeoxyglucosepositron emission tomographyin evaluation of bone marrowinvolvement by non-Hodgkin lymphoma.American Journal of Clinical Oncology. 2008; 31:409-12.Corresponding author e-mail: mdbugra@gmail.comOrcid ID:Buğra Sağlam 0000-0001-8342-990XAbdulkerim Yıldız 0000-0002-9596-4042Buğra Kaya 0000-0003-0650-0690Kültigin Türkmen 0000-0002-1667-7716Doi: 10.5505/aot.2022.39259www.actaoncologicaturcica.comCopyright©Ankara Onkoloji Hastanesi
Acta Oncologica Turcica 2022; 55: 9-159Original ArticleDiagnostic Value of 1.5 Tesla Multiparametric MRI in Prostate Cancer1.5 Tesla Multiparametrik MRG’nin Prostat Kanserinde Tanısal DeğeriÜlkü Bekar, Şehnaz TezcanKoru Hospital, Radiology Department, Ankara, TurkeyABSTRACTIntroduction: Although prostate biopsy is still the gold standard in diagnosis of prostate cancer (PC),multi-parametric MRI (MpMRI) applied with 1.5 Tesla (T) or 3T systems has become an indispensablemethod in diagnosis. We aimed to compare “Prostate Imaging-Reporting and Data System version2”(PI-RADSv2) scores with pathology of patients who underwent MpMRG (1.5T) for the suspicion ofPC.Methods: Between January 2017 and January 2020, 52 patients (26 benign, 26 malignant patients) whounderwent MpMRI followed by biopsy in our center due to suspicion of PC were included in our study.Age, prostate volume, blood PSA (prostate specific antigen) value, density and pathology of these caseswere analyzed. The PI-RADSv2 assessment category was assigned for each patient by an experiencedradiologist. The "Chi-square" test and "Student-t" test were used for statistical analysis.Results: The mean prostate volume of benign group (96.4±77.7) was significantly higher than patientswith cancer (47.4±17.3) (p=0.003). Mean PSA value and PSA density in patients with malignancy (PSAvalue, 13.7±16.5 ng/ml; PSA density, 0.33±0.46 ng/ml/cc) were significantly higher than benign group(PSA value, 6.8±3.3 ng/ml; PSA density, 0.09±0.05 ng/ml/cc, p<0,05). The sensitivity, specificity,negative predictive value and positive predictive value of MpMRI applied with 1.5 T system in detectionof significant PC was 73.08%, 84.62%, 82.61% and 75.86%, respectively.Discussion and Conclusion: Considering the high negative predictive value of negative MpMRIfindings for significant PC due to PI-RADSv2, MRI can reduce unnecessary biopsy.Keywords: Multiparametric magnetic resonance imaging, prostate biopsy, prostate cancer, ProstateImaging–Reporting and Data SystemÖZETGiriş ve Amaç: Prostat kanseri tanısında prostat biyopsisi halen altın standart tetkik olmakla birlikte1,5 Tesla (T) ya da 3 T cihazlarla uygulanan multi-parametrik MRG (MpMRG), tanıda vazgeçilmez birtetkik haline gelmiştir. Bu çalışmada; prostat kanseri şüphesiyle 1,5 T cihaz ile MpMRG yapılanhastaların, Prostat Görüntüleme Raporlama ve Bilgi Sistemi versiyon2 (PI-RADSv2) skorlarını, prostatbiyopsisi patoloji sonuçlarıyla karşılaştırmayı amaçladık.Yöntem ve Gereçler: Çalışmamıza kliniğimizde Ocak 2017-Ocak 2020 tarihleri arasında prostat kanserşüphesi nedeniyle MpMRG ve ardından prostat biyopsisi yapılmış 52 hasta (26 benign, 26 malign) dahiledildi. Bu olguların yaşı, prostat hacmi, kan PSA (prostat spesifik antijen) değeri, yoğunluğu ve patolojisonuçları analiz edildi. Deneyimli bir radyolog tarafından her bir hasta için PI-RADSv2 skorlamasistemine göre kategorizasyon yapıldı. İstatistiksel analizde “Ki kare” testi ile “Student-t” test kullanıldı.Bulgular: Benign hasta grubunun (96,4±77,7) ortalama prostat hacmi malign gruptan (47,4±17.3)anlamlı olarak daha yüksektir (p=0,003). Ortalama PSA değeri ve yoğunluğu malign hastalarda (PSAdeğeri, 13,7±16,5 ng/ml; PSA yoğunluğu, 0,33±0,46 ng/ml/cc) benign hasta grubundan (PSA değeri,6,8±3,3 ng/ml; PSA yoğunluğu, 0,09±0,05 ng/ml/cc; p<0,05) daha yüksektir. 1,5T cihaz ile uygulananMpMRG’nin anlamlı prostat kanseri saptamadaki sensitivitesi %73,08, spesifitesi %84,62 pozitifprediktif değeri %82,61 iken negatif prediktif değeri ise %75,86 olarak hesaplandı.First Received: 25.05.2021, Accepted: 11.10.2021doi: 10.5505/aot.2022.59140
Page 2 and 3: Acta Oncologica Turcica 2022EDITORI
Page 4 and 5: Acta Oncologica Turcica 20222any or
Page 6 and 7: Acta Oncologica Turcica 20224KEYWOR
Page 8 and 9: Acta Oncologica Turcica 20226found
Page 10 and 11: Value of ADC Thresholds to Diagnose
Page 12 and 13: Acta Oncologica Turcica 2022; 55: 1
Page 68 and 69:
Acta Oncologica Turcica 2022; 55: 5
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86:
show all

aot2022v55i1

Create successful ePaper yourself

Delete template?

Save as template?